ReviewBoneKEy reports2014
Bisphosphonates and bone quality.
Review in BoneKEy reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use of fractal analysis in dental images for osteoporosis detection: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Pooled it
- Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials.Scientific reports · 2018Pooled it
- Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Trial
- Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial.Clinical obesity · 2021Trial
- Review
- Effect of Depletion of Developmentally Regulated GTP Binding Protein on Osteoblastic Differentiation and Bone Microarchitecture.Journal of cellular and molecular medicine · 2025Article
- Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses.Equine veterinary journal · 2025Article
- PET/CT for the Opportunistic Screening of Osteoporosis and Fractures in Cancer Patients.Current osteoporosis reports · 2024Review
- Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.International journal of molecular sciences · 2024Review
- Association between perioperative blood transfusion and length of hospital stay in patients with osteoporotic fractures.BMC musculoskeletal disorders · 2023Article
- Biologics: Teriparatide and Newer Anabolics.Indian journal of orthopaedics · 2023Review
- Long-term consequences of osteoporosis therapy with bisphosphonates.Archives of endocrinology and metabolism · 2023Review
- Article
- Comparison of the prophylactic use of ibandronate and its use in early-stage osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head.Joint diseases and related surgery · 2023Article
- Association of 25-hydroxyvitamin D levels with lipid profiles in osteoporosis patients: a retrospective cross-sectional study.Journal of orthopaedic surgery and research · 2023Article
- Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- A 2,7-dichlorofluorescein derivative to monitor microcalcifications.Molecular systems design & engineering · 2022Article
- Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.Bone reports · 2022Article
- The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.Frontiers in medicine · 2022Article
- Bisphosphonates as Potential Inhibitors of Calcification in Bioprosthetic Heart Valves (Review).Sovremennye tekhnologii v meditsine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates (BPs) are bone-avid compounds used as first-line medications for the prevention and treatment of osteoporosis. They are also used in other skeletal pathologies such as Paget's and metastatic bone disease. They effectively reduce osteoclast viability and also activity in the resorptive phase of bone remodelling and help preserve bone micro-architecture, both major determinants of bone strength and ultimately of the susceptibility to fractures. The chemically distinctive structure of each BP used in the clinic determines their unique affinity, distribution/penetration throughout the bone and their individual effects on bone geometry, micro-architecture and composition or what we call 'bone quality'. BPs have no clinically significant anabolic effects. This review will touch upon some of the components of bone quality that could be affected by the administration of BPs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.